Boston Scientific Corp (BSX) stock
BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3050% below fair value
$44.20−0.93 (-2.06%)
Close on Nov 12, 2026Market cap $64.06BP/E 18.7Yield –
Boston Scientific ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Boston Scientific's ebitda for the twelve months ending Sep 30, 2026 was $5.36B, up 11.4% year over year. For fiscal 2025 it was $4.98B, up 28.6% from the year before. Over ten years it grew 26.2% a year on average. The highest annual figure on record is $4.98B in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.98B | +28.6% |
| FY2024 | Dec 31, 2024 | $3.87B | +9.4% |
| FY2023 | Dec 31, 2023 | $3.54B | +27.1% |
| FY2022 | Dec 31, 2022 | $2.79B | +21.5% |
| FY2021 | Dec 31, 2021 | $2.29B | +119.8% |
| FY2020 | Dec 31, 2020 | $1.04B | -58.8% |
| FY2019 | Dec 31, 2019 | $2.53B | +5.4% |
| FY2018 | Dec 31, 2018 | $2.40B | +12.7% |
| FY2017 | Dec 31, 2017 | $2.13B | +68.7% |
| FY2016 | Dec 31, 2016 | $1.26B | +159.7% |
| FY2015 | Dec 31, 2015 | $486.00M | +14.6% |
| FY2014 | Dec 31, 2014 | $424.00M | -47.6% |
| FY2013 | Dec 31, 2013 | $809.00M | – |
| FY2012 | Dec 31, 2012 | -$3.19B | -296.5% |
| FY2011 | Dec 31, 2011 | $1.62B | +913.1% |
| FY2010 | Dec 31, 2010 | $160.00M | – |
| FY2009 | Dec 31, 2009 | -$60.00M | – |
| FY2008 | Dec 31, 2008 | -$641.00M | -170.9% |
| FY2007 | Dec 31, 2007 | $904.00M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.19B | -14.5% |
| Q2 FY2026 | Jun 30, 2026 | $1.53B | +32.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.45B | +16.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.19B | +16.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.39B | +33.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.16B | +39.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.25B | +27.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.02B | +14.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.04B | +4.6% |
| Q2 FY2024 | Jun 30, 2024 | $831.00M | +2.3% |
| Q1 FY2024 | Mar 31, 2024 | $979.00M | +17.0% |
| Q4 FY2023 | Dec 31, 2023 | $897.00M | +28.9% |
| Q3 FY2023 | Sep 30, 2023 | $993.00M | +54.7% |
| Q2 FY2023 | Jun 30, 2023 | $812.00M | +14.9% |
| Q1 FY2023 | Mar 31, 2023 | $837.00M | +13.1% |
| Q4 FY2022 | Dec 31, 2022 | $696.00M | +48.1% |
| Q3 FY2022 | Sep 30, 2022 | $642.00M | -2.6% |
| Q2 FY2022 | Jun 30, 2022 | $707.00M | +34.7% |
| Q1 FY2022 | Mar 31, 2022 | $740.00M | +16.0% |
| Q4 FY2021 | Dec 31, 2021 | $470.00M | +38.6% |
| Q3 FY2021 | Sep 30, 2021 | $659.00M | +755.8% |
| Q2 FY2021 | Jun 30, 2021 | $525.00M | +157.4% |
| Q1 FY2021 | Mar 31, 2021 | $638.00M | +50.8% |
| Q4 FY2020 | Dec 31, 2020 | $339.00M | – |
| Q3 FY2020 | Sep 30, 2020 | $77.00M | – |
| Q2 FY2020 | Jun 30, 2020 | $204.00M | – |
| Q1 FY2020 | Mar 31, 2020 | $423.00M | – |
See a number that looks wrong?